| Literature DB >> 33931816 |
Chihiro Miyagi1, Barry D Kuban2,3, Christine R Flick1, Anthony R Polakowski1, Takuma Miyamoto1, Jamshid H Karimov1, Randall C Starling4,5, Kiyotaka Fukamachi1.
Abstract
A novel pump, the left atrial assist device (LAAD), is a device specifically for the treatment of heart failure with preserved ejection fraction (HFpEF). The LAAD is a mixed-flow pump that is implanted in the mitral position and delivers blood from the left atrium to the left ventricle. During the development process, we aimed to explore whether device activation in torque control (TC) mode would improve the function of the LAAD. The TC mode causes adjustment of the pump speed automatically during each cardiac cycle in order to maintain a specified torque. In this study, we tested four different TC settings (TC modes 0.9, 1.0, 1.25, and 1.5) using an in vitro mock circulatory loop. Mild, moderate, and severe diastolic heart failure (DHF) conditions, as well as normal heart condition, were simulated with the four TC modes. Also, we evaluated the LAAD in vivo with three calves. The LAAD was implanted at the mitral position with four TC settings (TC modes 0.9, 1.0, 1.1, 1.2). With LAAD support, the in vitro cardiac output and aortic pressure recovered to normal heart levels at TC 1.25 and 1.5 even under severe DHF conditions with little pump regurgitation. The TC mode tested in vivo with three calves, and it also showed favorable result without elevating the left ventricular end-diastolic pressure. These initial in vitro and in vivo results suggest that the TC mode could be potentially effective, and the LAAD could be a treatment option for HFpEF patients.Entities:
Keywords: Continuous-flow assist device; Device-based therapy; Diastolic dysfunction; Mechanical circulatory support
Year: 2021 PMID: 33931816 DOI: 10.1007/s10741-021-10117-6
Source DB: PubMed Journal: Heart Fail Rev ISSN: 1382-4147 Impact factor: 4.214